The IN VIVO Blog (blog) | Deals Of the Week, Once Again, Ponders Biosimilars The IN VIVO Blog (blog) Like their competitors, Teva and Lonza held much of their work close to their vests, but they had counted on developing a franchise around a biosimilar version of Roche's $7 billion Rituxan (rituximab) franchise, only to halt clinical development last ... |
